Skip to main content
OpenTrials
Completed

NCT Number: NCT01580293

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

Haemophilia A is an inherited disorder in which one of the proteins, Factor VIII, needed to form blood clots is missing or not present in sufficient levels. In a person with haemophilia A, the clotting process is slowed and the person experiences bleeds that can result in serious problems and potential disability.

The current standard treatment for severe haemophilia A is regularly scheduled infusion of FVIII to keep levels high enough to prevent bleeding. Due to the short half-life of FVIII, prophylaxis may require treatment as often as every other day.

In this trial safety and efficacy of a long-acting recombinant factor VIII molecule is evaluated in subjects with severe Hemophilia A.

120-140 patients will receive open label treatment with long-acting rFVIII either on-demand to treat bleeds or prophylactically for 36 weeks in the main trial plus an optional extension to continue treatment for at least 100 total exposure days (ED). Patients on prophylactic treatment will receive study drug at dosing intervals between once and twice a week depending on their observed bleeding. Patients will attend the treatment centre for routine blood samples and be required to keep an electronic diary.

Male patients aged 12-65, with severe hemophilia A, previously treated with FVIII for at least 50 exposure days may be eligible for this study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year–65 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Vienna, Austria

Loading trial locations.

About this study

Subjects in prophylactic treatment arms will undergo clinical evaluation at 10 weeks. Those with adequate control of bleeding will undergo randomization to every 5 or 7 day infusion. Those with continued bleeding will remain in treatment arm and have an increase in dose.

Part B-major surgery - optional sub study included to collect information on efficacy of BAY94-9027 in major surgical setting. Due to rarity of surgery in this population, enrollment to this sub-study may be independent of participation in main study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male; 12-65 years of age
  • Subjects with severe hemophilia A
  • Previously treated with factor VIII for a minimum of 150 exposure days

Exclusion criteria

  • Inhibitors to FVIII (current evidence or history)
  • Any other inherited or acquired bleeding disorder in addition to Hemophilia A
  • Platelet count < 100,000/mm3
  • Creatinine > 2x upper limit of normal or AST/ALT (aspartate aminotransferase/alanine aminotransferase) > 5x upper limit of normal

Treatment and study plan

BAY94-9027

Biological

Intravenous infusion of BAY94-9027

Primary outcomes

  1. Annualized Number of Total Bleeds in On-demand Treatment Arm (Weeks 0 -36) and in Each Prophylaxis Arm (Weeks 10 - 36, Excluding Rescue Bleeds) - Part A, Main Trial

    Time frame: On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A

    Annualized number of total bleeds was defined as the annualized sum of spontaneous bleeds and trauma bleeds. A participant who had the one-time increase in dose frequency was regarded as rescued. A rescue bleed was a bleed that occured after the dose frequency was increased. Rescue bleeds and periods were not considered for the annualized bleeding rate (ABR).

Secondary outcomes

  1. Annualized Number of Joint Bleeds, Trauma, Spontaneous Bleeds in On-demand Treatment Arm (Weeks 0 -36) and in Each Prophylaxis Arm (Weeks 10 - 36, Excluding Rescue Bleeds) - Part A

    Time frame: On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A

    A participant who had the one-time increase in dose frequency was regarded as rescued. A rescue bleed was a bleed that occured after the dose frequency was increased. Rescue bleeds and periods were not considered for the ABR.

  2. Annualized Number of Total Bleeds in On-demand Treatment Arm and in Each Prophylaxis Arm, Part A, Extension

    Time frame: at least 100 total exposure days acquired, median time 3.9 years up to 7 years maximum

    Annualized number of total bleeds was defined as the annualized sum of spontaneous bleeds and trauma bleeds.

  3. Number of Participants Developed Human Coagulation Factor VIII (FVIII) Inhibitor - Part A

    Time frame: Weeks 0 to 36 during Part A

    FVIII inhibitor testing was done according to the Nijmegen modified Bethesda assay. A positive inhibitor test was defined with a threshold of ≥0.6 Bethesda unit (BU) at the central laboratory.

  4. Number of Bleeds Requiring 1, 2 or >= 3 Infusions to Control the Bleed - Part A

    Time frame: Weeks 0 to 36

    Number of bleeds requiring 1, 2 or >= 3 infusions to control the bleeding

  5. Number of Bleeds According to Locations - Part A

    Time frame: Weeks 0 -36

    Bleed locations were categorised as joint, muscle, skin/mucosa, internal, others and missing.

  6. Number of Bleeds Over Time Since Previous Prophylaxis Infusion - Part A

    Time frame: Weeks 0 to 36

  7. Number of Bleeds According to Participant's Assessment of Response to Treatment - Part A

    Time frame: Weeks 0 to 36 during Part A

    Response to treatment was assessed by participant as excellent, good, moderate, poor or missing during Part A of the study.

  8. Recombinant Human Factor VIII (rFVIII) Usage Expressed as Total Dose Per Kilogram Per Year - Part A

    Time frame: On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A

    For prophylaxis patients, the dose is related to all infusions.

  9. Recombinant Human Factor VIII (rFVIII) Usage Expressed as Dose Per Kilogram Per Infusion - Part A

    Time frame: On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A

    For prophylaxis patients, the dose per infusion related to prophylaxis infusion.

  10. Number of Participants Requiring an Increase in Dose Frequency, or Dose Increase, During Weeks 10 to 36 - Part A

    Time frame: Weeks 10 to 36 during Part A

  11. Number of Surgeries According to Physician's Assessment of Adequacy of Hemostasis in Major Surgery - Part B

    Time frame: Day of surgery

    Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill. Adequacy of hemostasis was assessed as excellent, good, moderate or poor, by the surgeon or interventionalist during Part B of the study.

  12. Recombinant Human Factor VIII (rFVIII) Usage Expressed as Dose Per Kilogram Per Infusion for Major Surgery - Part B

    Time frame: Up to 3 weeks post-surgery during Part B

    Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill. Total dose per kilogram per Infusion was expressed in international units per kilogram per infusion (IU/kg/infusion).

  13. Recombinant Human Factor VIII (rFVIII) Usage Expressed as Number of Infusions for Major Surgery - Part B

    Time frame: Up to 3 weeks post-surgery during Part B

    Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.rFVIII usage expressed as number of infusions and IU/kg per year, as well as IU/kg per event (surgery) was assessed by investigator.

  14. Maximum Drug Plasma Concentration (Cmax) Following Single and Multiple Doses of BAY94-9027, Chromogenic Assay - Part A

    Time frame: Weeks 0 and 36: pre-infusion (0 hours), post-infusion 15, 30 minutes, 1, 3, 6, 8, 24, 48, 72, 96 hours

    Cmax: Maximum observed drug concentration following an infusion of 60 IU/kg

  15. Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC) Following Single and Multiple Doses of BAY94-9027, Chromogenic Assay - Part A

    Time frame: Weeks 0 and 36: pre-infusion (0 hours), post-infusion 15, 30 minutes, 1, 3, 6, 8, 24, 48, 72, 96 hours

    AUC: The total area under the plasma concentration versus time curve following an infusion of 60 IU/kg .

  16. Terminal Elimination Half Life (t1/2) Following Single and Multiple Doses of BAY94-9027, Chromogenic Assay - Part A

    Time frame: Weeks 0 and 36: pre-infusion (0 hours), post-infusion 15, 30 minutes, 1, 3, 6, 8, 24, 48, 72, 96 hours

    t1/2: Terminal half-life is the time the plasma concentration during terminal phase is halved following an infusion of 60 IU/kg .

  17. Overall Human Coagulation Factor VIII (FVIII) Recovery Value by Chromogenic Assay - Part A

    Time frame: Weeks 0 to 36 during Part A

    Recovery was calculated by the following formula: Recovery = (post-infusion FVIII activity - pre-infusion FVIII activity ) * weight / dose (in IU). Recovery is the increase of FVIII activity after the injection normalized by dose: IU/dl per IU/kg = kg/dL

  18. Change From Baseline in Quality of Life by Hemophilia Specific Quality of Life Instrument or Questionnaire for Adults (Haemo-QoL-A) Overall Score at Week 36 - Part A

    Time frame: Week 0 (baseline) and Week 36 during Part A

    Quality of life (QoL) was measured by the Haemo-QoL-A overall score, which ranged from 0 (the worst condition) to 100 (the best condition).

Other outcomes

  1. Change From Baseline in Overall Pain Severity and Interference Due to Pain at Week 36 - Part A

    Time frame: Week 0 (baseline) and Week 36 during Part A

    Brief Pain Inventory (BPI) - Short Form (BPI-SF) was a 15-item, self-administered, validated tool developed to assess pain used in the study for patient reported outcomes. Scores ranged from 0 to 10 and a higher score indicates a higher level of pain/interference.

  2. Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire at Week 36 - Part A

    Time frame: Week 0 (baseline) and Week 36 during Part A

    The WPAI is a validated instrument to assess the effect of hemophilia on ability to work, attend classes, and perform regular daily activities in participants aged 12 and above. The WPAI also contained classroom impairment questions (CIQ). The questionnaire was self-administered and comprised of nine questions that elicited information on work, classroom, and daily activity impairment during the previous seven days. WPAI outcomes that are overall work and activity impairment, transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.

  3. Recombinant Human Factor VIII (rFVIII) Usage Expressed as Number of Infusions- Part A

    Time frame: On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A

    For prophylaxis patients, the dose is related to all infusions.

  4. Recombinant Human Factor VIII (rFVIII) Usage Expressed as Dose Per Kilogram With Prophylaxis Treatment - Part A

    Time frame: Weeks 10 - 36 during Part A

    For prophylaxis patients, the dose per kilogram is related to prophylaxis infusions.

  5. Number of Minor Surgeries According to Physician's Assessment of Adequacy of Hemostasis - Part A

    Time frame: Weeks 0 to 36 during Part A

    Minor surgery was defined as any surgical procedure that did not meet the definition of major, and included simple dental extractions, incision and drainage of abscesses, or simple excisions.

  6. Number of Surgeries According to Physician's Assessment of Response to Hemostasis, Post-surgery - Part B Main Trial

    Time frame: Up to 3 weeks post-surgery during Part B

    Response to treatment during surgery was assessed by investigator/surgeon as excellent, good, moderate, poor or missing during Part B of the study.

  7. Number of Participants With Change/Drop in Hemoglobin/Hematocrit Laboratory Assessments - Part B

    Time frame: Up to 3 weeks post-surgery during Part B

    Hematocrit is defined as the volume percentage (%) of red blood cells in blood.

  8. Maximum Blood Loss During Major Surgery - Part B

    Time frame: day of surgery

    Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.

  9. Number of Participants Who Took Anti-fibrinolytic Medications During Major Surgery - Part B

    Time frame: Up to 3 weeks post-surgery during Part B

    Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.

  10. Volume of Blood Transfused in Major Surgery - Part B

    Time frame: Up to 3 weeks post-surgery during Part B

    Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

A Phase II/III, Multicenter, Partially Randomized, Open Label Trial Investigating Safety and Efficacy of On-demand and Prophylactic Treatment With BAY94-9027 in Severe Hemophilia A

Acronym: PROTECT-VIII

Important dates

Study start
2012
Primary completion
2014
Study completion
2019
First posted
Apr 19, 2012
Registry last updated
Nov 7, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.